Posts tagged: multiple

The complement system is essential in the pathogenesis of inflammatory central nervous system disorders.

OBJECTIVE: The purpose of this study was to explore brain MRI findings in neuromyelitis optica (NMO) and to investigate specific brain lesions with respect to the localization of aquaporin-4 (AQP-4). MATERIALS AND METHODS: Forty admitted patients (36 women) who satisfied the 2006 criteria of Wingerchuk et al. for NMO were included in this study

OBJECTIVES: To analyze the role of HLA-DRB1 and -DPB1 alleles in the pathogenesis of neuromyelitis optica (NMO) and multiple sclerosis in Southern Han Chinese. METHODS: Thirty serum anti-aquaporin 4 antibodies (AQP4-Ab)-positive NMO patients, 53 conventional multiple sclerosis (C-MS) patients, and 93 controls (CTLs) were enrolled. The HLA-DRB1 and -DPB1 alleles of the subjects were determined by sequencing-based typing (SBT)

It may be possible to save money by treating multiple sclerosis and neuromyelitis optica with lower doses of rituximab, but the result may be a shorter period of effectiveness, according to one study.

Anti-aquaporin-4 (Aqp-4) antibody and complement system have emerged as major pathogenic factors in neuromyelitis optica (NMO). To test the significance of interleukin-6 (IL-6), another important humoral immunity factor, in NMO pathogenesis, we measured serum and cerebrospinal fluid (CSF) IL-6 levels of 23 NMO, 11 transverse myelitis, 16 optic neuritis, 27 relapsing remitting multiple sclerosis patients, and 20 neurologically normal controls

BACKGROUND: Few data exist on a possible benign form of neuromyelitis optica (NMO). OBJECTIVES: To identify NMO with a good outcome (go-NMO) among a large population of patients and to describe demographic and clinical variables associated with go-NMO vs standard NMO and benign multiple sclerosis.

BACKGROUND: Under the therapeutic point of view, neuromyelitis optica (NMO) poses major challenges. Patients with NMO manifest severe disability from recurrent demyelinating lesions and the therapies are only partially effective. We performed a retrospective analysis of the records of patients followed at our institution and provide suggestions for management of acute relapses and preventive therapy.

The detection of aquaporin-4 (AQP4) antibodies in neuromyelitis optica (NMO) led to a breakthrough in diagnosing NMO. To date, different assays to detect these antibodies are available.

Neuromyelitis optica (NMO) is an autoimmune disease of the central nervous system characterized by severe demyelinating inflammatory attacks typically affecting the spinal cord and optic nerves. Anti-aquaporin-4(AQP4) serum autoantibodies are present in approximately 70% of NMO patients. Those antibodies probably are pathogenic and the titers are elevated during relapse as compared with those in remission

Neuromyelitis Optica (NMO) is a rare but severe demyelinating disease, characterized by severe optic neuritis and spinal myelitis. The entity was described by Eug?ne Devic in 1894 and is since then known as Devic’s Neuromyelitis Optica (1). Initially considered a monophasic variant of multiple sclerosis (MS), detailed recent reports have allowed a better definition of the disease with distinct clinical, laboratory and imaging findings.

Background: Neuromyelitis optica (NMO) is a rare inflammatory disease. Average age at onset is 35 years

BACKGROUND: Interferon-β-1b (IFNβ-1b) has been used to prevent exacerbation of relapsing-remitting multiple sclerosis (RRMS) including optic-spinal multiple sclerosis (OSMS) in Japan. We encountered 2 patients with OSMS with unexpectedly severe exacerbation soon after the initiation of IFNβ-1b therapy. The experience urged us to retrospectively review the patients with RRMS who had been treated with IFNβ-1b to identify similar cases.